journal article·2022-11

Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer

Wenjuan Ma, Yuting Yang, Jianwei Zhu, Weiqiang Jia, Tao Zhang, Zhiqiang Liu, Xingyu Chen, Yunfeng Lin

Advanced Materials· Volume 34· Issue 46
Publisher page

Abstract

Abstract DNA materials have emerged as potential nanocarriers for targeted cancer therapy to precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of DNA materials due to their interception by the reticuloendothelial system and blood clearance further limit their clinical translation. This study employs an HER2‐targeted DNA‐aptamer‐modified DNA tetrahedron (HApt‐tFNA) as a drug delivery system, and combines maytansine (DM1) to develop the HApt‐DNA tetrahedron/DM1 conjugate (HApt‐tFNA@DM1, HTD, HApDC) for targeted therapy of HER2‐positive cancer. To optimize the pharmacokinetics and tumor‐aggregation of HTD, a biomimetic camouflage is applied to embed HTD. The biomimetic camouflage is constructed by merging the erythrocyte membrane with pH‐responsive functionalized synthetic liposomes, thus with excellent performance of drug delivery and tumor‐stimulated drug release. The hybrid erythrosome‐based nanoparticles show better inhibition of HER2‐positive cancer than other drug formulations and exhibit superior biosafety. With the strengths of precise delivery, increased drug loading, sensitive tumor probing, and prolonged circulation time, the HApDC represents a promising nanomedicine to treat HER2‐positive tumors. Notably, this study developsa dual‐targeting nanoparticle by combining pH‐sensitive camouflage and HApDC, initiating an important step toward the development and application of DNA‐based medicine and biomimetic cell membrane materials in cancer treatment and other potential biological applications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu 610041 P. R. China

Department of Neurosurgery Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu 611731 P. R. China

College of Biomedical Engineering Sichuan University Chengdu 610041 P. R. China

Funding

National Natural Science Foundation of China

References (58)

Show source-provided references
1. 10.1016/S0140-6736(16)32417-510.1016/S0140-6736(16)32417-5 ↗
2. 10.1159/00005539610.1159/000055396 ↗
3. 10.1021/acsnano.6b0591010.1021/acsnano.6b05910 ↗
4. 10.1038/s41565-019-0626-410.1038/s41565-019-0626-4 ↗
5. 10.1038/s41419-020-03349-110.1038/s41419-020-03349-1 ↗
6. 10.1016/S0140-6736(10)61121-X10.1016/S0140-6736(10)61121-X ↗
7. 10.1007/s10120-011-0118-110.1007/s10120-011-0118-1 ↗
8. 10.1016/j.ccell.2015.12.00810.1016/j.ccell.2015.12.008 ↗
9. 10.1038/mt.2015.17810.1038/mt.2015.178 ↗
10. 10.1016/S0140-6736(19)31774-X10.1016/S0140-6736(19)31774-X ↗
11. 10.1126/science.115453310.1126/science.1154533 ↗
12. 10.1038/382609a010.1038/382609a0 ↗
13. 10.1038/nature0797110.1038/nature07971 ↗
14. 10.1038/350631a010.1038/350631a0 ↗
15. 10.1021/acs.chemrev.0c0029410.1021/acs.chemrev.0c00294 ↗
16. 10.1038/s41596-020-0355-z10.1038/s41596-020-0355-z ↗
17. 10.1021/acs.nanolett.1c0113110.1021/acs.nanolett.1c01131 ↗
18. 10.1007/s40820-021-00614-610.1007/s40820-021-00614-6 ↗
19. 10.1002/adma.20210782010.1002/adma.202107820 ↗
20. 10.1002/smll.20210435910.1002/smll.202104359 ↗
21. 10.1007/978-1-4939-2727-2_110.1007/978-1-4939-2727-2_1 ↗
22. 10.1016/j.omtn.2017.12.01510.1016/j.omtn.2017.12.015 ↗
23. 10.1021/acs.nanolett.9b0132010.1021/acs.nanolett.9b01320 ↗
24. 10.1016/j.addr.2018.08.00510.1016/j.addr.2018.08.005 ↗
25. 10.1038/s41392-021-00727-910.1038/s41392-021-00727-9 ↗
26. 10.1158/0008-5472.CAN-10-092010.1158/0008-5472.CAN-10-0920 ↗
27. 10.1016/j.jconrel.2015.01.03210.1016/j.jconrel.2015.01.032 ↗
28. 10.1021/acs.bioconjchem.0c0025010.1021/acs.bioconjchem.0c00250 ↗
29. 10.1016/j.biomaterials.2018.08.02110.1016/j.biomaterials.2018.08.021 ↗
30. 10.1016/j.biomaterials.2015.07.02510.1016/j.biomaterials.2015.07.025 ↗
31. 10.1021/acs.bioconjchem.0c0007110.1021/acs.bioconjchem.0c00071 ↗
32. 10.3390/molecules2420378110.3390/molecules24203781 ↗
33. 10.3390/molecules2501000310.3390/molecules25010003 ↗
34. 10.1126/sciadv.abg416810.1126/sciadv.abg4168 ↗
35. 10.1038/s41467-018-04535-810.1038/s41467-018-04535-8 ↗
36. 10.1038/ncomms1578710.1038/ncomms15787 ↗
37. 10.1021/acsnano.9b0597610.1021/acsnano.9b05976 ↗
38. 10.3390/molecules2615456310.3390/molecules26154563 ↗
39. 10.1016/j.jconrel.2021.11.01410.1016/j.jconrel.2021.11.014 ↗
40. 10.1056/NEJMoa181401710.1056/NEJMoa1814017 ↗
41. 10.1158/0008-5472.CAN-08-177610.1158/0008-5472.CAN-08-1776 ↗
42. 10.1021/acsami.1c0729710.1021/acsami.1c07297 ↗
43. 10.1002/adma.20170675910.1002/adma.201706759 ↗
44. 10.1016/j.actbio.2020.05.02810.1016/j.actbio.2020.05.028 ↗
45. 10.1021/nl500618u10.1021/nl500618u ↗
46. 10.1002/adma.20190079510.1002/adma.201900795 ↗
47. 10.1016/j.biomaterials.2018.01.01810.1016/j.biomaterials.2018.01.018 ↗
48. 10.1039/C7NR07130B10.1039/C7NR07130B ↗
49. 10.1021/acsami.9b0924310.1021/acsami.9b09243 ↗
50. 10.1021/acsami.0c0811210.1021/acsami.0c08112 ↗
51. 10.1021/acsnano.9b0945310.1021/acsnano.9b09453 ↗
52. 10.1126/sciadv.aaw687010.1126/sciadv.aaw6870 ↗
53. 10.1158/1535-7163.MCT-10-064510.1158/1535-7163.MCT-10-0645 ↗
54. 10.1039/C7CC09397G10.1039/C7CC09397G ↗
55. 10.1038/s41467-020-18245-710.1038/s41467-020-18245-7 ↗
56. 10.1016/j.neuron.2018.09.01710.1016/j.neuron.2018.09.017 ↗
57. 10.1111/cpr.1251110.1111/cpr.12511 ↗
58. 10.1039/C7NR09692E10.1039/C7NR09692E ↗